# BPC-157 TB-500 References: The Primary Research and Regulatory Citations

> BPC-157 TB-500 references: the primary research citations behind the Wolverine blend — tendon, angiogenesis, actin-sequestration, and wound studies — plus the FDA 503A regulatory sources. With DOIs and PubMed links.

Every quantitative claim on this site resolves to a numbered entry below — the primary peptide research and the FDA regulatory record.

## How to read this register

These are the [primary research citations](/references) behind the BPC-157 TB-500 site. Entries 1-11 are the peer-reviewed peptide literature for the two constituents; entries 12-13 are the FDA regulatory sources behind the [Wolverine legal status](/legal-status) page. The blend itself has no controlled trial, so every entry describes a single compound — BPC-157 or Thymosin Beta-4 / TB-500 — not the combination. Each carries a DOI or a PubMed link for verification. For the same findings answered question by question, see the [frequently asked questions](/faq).

## References

[1] Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. https://pubmed.ncbi.nlm.nih.gov/14554208/
[2] Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. https://pubmed.ncbi.nlm.nih.gov/27847966/
[3] Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004. https://pubmed.ncbi.nlm.nih.gov/15329672/
[4] Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012. https://pubmed.ncbi.nlm.nih.gov/22074294/
[5] Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999. https://pubmed.ncbi.nlm.nih.gov/10469335/
[6] Philp D, et al. Thymosin beta4 increases hair growth by activation of hair follicle stem cells. FASEB J. 2004. https://pubmed.ncbi.nlm.nih.gov/14657002/
[7] Philp D, et al. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004. https://pubmed.ncbi.nlm.nih.gov/15037013/
[8] Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012. https://pubmed.ncbi.nlm.nih.gov/22962027/
[9] Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. https://pubmed.ncbi.nlm.nih.gov/40756949/
[10] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. https://pubmed.ncbi.nlm.nih.gov/41966639/
[11] Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Experimental Lower-Extremity Ischemia-Reperfusion Injury. Medicina (Kaunas). 2025;61(2):291. https://pubmed.ncbi.nlm.nih.gov/40005408/
[12] U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (Category 2; BPC-157 and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" entries effective with the September 29, 2023 update); and Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
[13] U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (agenda lists BPC-157 and TB-500 as bulk drug substances being considered for inclusion on the 503A Bulks List). https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026

---

A glazed-tile reading panel on the BPC-157 TB-500 blend — each tendon, wound, and angiogenesis study set in its own tile beside the FDA 503A and access record, with no clinic behind the panel and nothing here dispensed.